Similar articles for PMID: 31434554

Year	Number of Results
2004	1
2006	4
2007	10
2008	6
2009	13
2010	5
2011	8
2012	12
2013	16
2014	8
2015	5
2016	3
2017	5
2018	15
2019	7
2020	4
2021	1

1

The challenges of handling deferasirox in sickle cell disease patients older than 40 years.

Ribeiro LB, Soares EA, Costa FF, Gilli SCO, Olalla Saad ST, Benites BD. Ribeiro LB, et al. Hematology. 2019 Dec;24(1):596-600. doi: 10.1080/16078454.2019.1657667. Hematology. 2019. PMID: 31434554

2

Deferasirox for managing transfusional iron overload in people with sickle cell disease.

Meerpohl JJ, Antes G, Rücker G, Fleeman N, Niemeyer C, Bassler D. Meerpohl JJ, et al. Cochrane Database Syst Rev. 2010 Aug 4;(8):CD007477. doi: 10.1002/14651858.CD007477.pub2. Cochrane Database Syst Rev. 2010. PMID: 20687088 Review.

3

Desferrioxamine mesylate for managing transfusional iron overload in people with transfusion-dependent thalassaemia.

Fisher SA, Brunskill SJ, Doree C, Gooding S, Chowdhury O, Roberts DJ. Fisher SA, et al. Cochrane Database Syst Rev. 2013 Aug 21;(8):CD004450. doi: 10.1002/14651858.CD004450.pub3. Cochrane Database Syst Rev. 2013. PMID: 23963793 Review.

4

Tolerability and efficacy of deferasirox in patients with transfusional iron overload: results from a German 2-year non-interventional study.

Nolte F, Nückel H, Schmidt B, Geer T, Rubanov O, Hebart H, Jarisch A, Albrecht S, Johr C, Schumann C, Hofmann WK. Nolte F, et al. J Cancer Res Clin Oncol. 2018 Aug;144(8):1531-1538. doi: 10.1007/s00432-018-2665-x. Epub 2018 May 14. J Cancer Res Clin Oncol. 2018. PMID: 29761371

5

Long-term safety and efficacy of deferasirox (Exjade) for up to 5 years in transfusional iron-overloaded patients with sickle cell disease.

Vichinsky E, Bernaudin F, Forni GL, Gardner R, Hassell K, Heeney MM, Inusa B, Kutlar A, Lane P, Mathias L, Porter J, Tebbi C, Wilson F, Griffel L, Deng W, Giannone V, Coates T. Vichinsky E, et al. Br J Haematol. 2011 Aug;154(3):387-97. doi: 10.1111/j.1365-2141.2011.08720.x. Epub 2011 May 19. Br J Haematol. 2011. PMID: 21592110 Free PMC article. Clinical Trial.

6

A randomised comparison of deferasirox versus deferoxamine for the treatment of transfusional iron overload in sickle cell disease.

Vichinsky E, Onyekwere O, Porter J, Swerdlow P, Eckman J, Lane P, Files B, Hassell K, Kelly P, Wilson F, Bernaudin F, Forni GL, Okpala I, Ressayre-Djaffer C, Alberti D, Holland J, Marks P, Fung E, Fischer R, Mueller BU, Coates T; Deferasirox in Sickle Cell Investigators. Vichinsky E, et al. Br J Haematol. 2007 Feb;136(3):501-8. doi: 10.1111/j.1365-2141.2006.06455.x. Br J Haematol. 2007. PMID: 17233848 Free PMC article. Clinical Trial.

7

Efficacy and safety of deferasirox compared with deferoxamine in sickle cell disease: two-year results including pharmacokinetics and concomitant hydroxyurea.

Vichinsky E, Torres M, Minniti CP, Barrette S, Habr D, Zhang Y, Files B; study CICL670A2201 investigators. Vichinsky E, et al. Am J Hematol. 2013 Dec;88(12):1068-73. doi: 10.1002/ajh.23569. Epub 2013 Sep 19. Am J Hematol. 2013. PMID: 23946212 Free article. Clinical Trial.

8

Deferasirox (Exjade) for the treatment of iron overload.

Cappellini MD, Taher A. Cappellini MD, et al. Acta Haematol. 2009;122(2-3):165-73. doi: 10.1159/000243801. Epub 2009 Nov 10. Acta Haematol. 2009. PMID: 19907154 Free article.

9

Deferasirox in children with transfusion-dependent thalassemia or sickle cell anemia: A large cohort real-life experience from Turkey (REACH-THEM).

Antmen B, Karakaş Z, Yeşilipek MA, Küpesiz OA, Şaşmaz İ, Uygun V, Kurtoğlu E, Oktay G, Aydogan G, Akın M, Salcioglu Z, Vergin C, Kazancı EG, Ünal S, Çalışkan Ü, Aral YZ, Türkkan E, Meral Güneş A, Tunç B, Gümrük F, Ayhan AC, Söker M, Koç A, Oymak Y, Ertem M, Timur Ç, Yıldırmak Y, İrken G, Apak H, Biner B, Eren TG, Işık Balcı Y, Koçak Ü, Karasu G, Akkaynak D, Patıroğlu T. Antmen B, et al. Eur J Haematol. 2019 Feb;102(2):123-130. doi: 10.1111/ejh.13180. Epub 2018 Dec 9. Eur J Haematol. 2019. PMID: 30300449

10

Persistence and compliance of deferoxamine versus deferasirox in Medicaid patients with sickle-cell disease.

Jordan LB, Vekeman F, Sengupta A, Corral M, Guo A, Duh MS. Jordan LB, et al. J Clin Pharm Ther. 2012 Apr;37(2):173-81. doi: 10.1111/j.1365-2710.2011.01276.x. Epub 2011 May 18. J Clin Pharm Ther. 2012. PMID: 21592159

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed